Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:brand |
gptkb:Cipro
gptkb:Avelox Floxin Levaquin |
| gptkbp:class |
synthetic antibiotics
|
| gptkbp:clinical_use |
respiratory infections
skin infections urinary tract infections gastrointestinal infections plague treatment bone and joint infections anthrax treatment chronic prostatitis typhoid fever treatment |
| gptkbp:contraindication |
gptkb:children
pregnancy |
| gptkbp:development |
gptkb:1980s
|
| gptkbp:example |
gptkb:ciprofloxacin
gptkb:moxifloxacin levofloxacin ofloxacin norfloxacin |
| gptkbp:formulation |
gptkb:Software_Solutions
gptkb:tablet suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
fluoroquinolone
|
| gptkbp:interacts_with |
gptkb:theophylline
gptkb:warfarin antacids |
| gptkbp:is_monitored_by |
renal function
liver function |
| gptkbp:mechanism_of_action |
inhibits DNA gyrase
|
| gptkbp:pharmacokinetics |
high bioavailability
broad spectrum concentration-dependent killing post-antibiotic effect tissue penetration |
| gptkbp:regulatory_compliance |
prescription only
|
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:side_effect |
nausea
diarrhea photosensitivity tendon rupture hypersensitivity reactions QT prolongation CNS effects |
| gptkbp:targets |
Gram-negative bacteria
Gram-positive bacteria |
| gptkbp:used_for |
bacterial infections
|
| gptkbp:water_resistance |
bacterial resistance
|
| gptkbp:bfsParent |
gptkb:Cipro
|
| gptkbp:bfsLayer |
6
|